Technical Analysis for BSGM - BioSig Technologies, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Inside Day | Range Contraction | 2.48% | |
| Wide Bands | Range Expansion | 2.48% | |
| Doji - Bearish? | Reversal | 6.45% | |
| Wide Bands | Range Expansion | 6.45% | |
| Crossed Above 20 DMA | Bullish | 4.43% | |
| Earnings Movers | Other | 4.43% | |
| Wide Bands | Range Expansion | 4.43% | |
| Oversold Stochastic | Weakness | 4.43% | |
| 20 DMA Resistance | Bearish | 17.02% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | 1 day ago |
| Up 5% | 1 day ago |
| Rose Above Previous Day's High | 1 day ago |
| Up 3% | 1 day ago |
| Up 2% | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/13/2024
BioSig Technologies, Inc. Description
BioSig Technologies is a medical device company developing a proprietary biomedical signal processing technology designed to improve the $4.6 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System. The technology has been developed to address an unmet need in a large and growing market. The Company’s first product, PURE EP(TM) System, is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias: Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and received FDA 510(k) clearance for the PURE EP(TM) System in August 2018.
Classification
Sector: Healthcare
Industry: Medical Devices
Keywords: Catheter FDA Ablation Cardiac Electrophysiology Technology Development Cardiac Arrhythmia Signal Processing Physiology Atrial Fibrillation Electrophysiology Circulatory System Arrhythmia Cardiovascular System Processing Technology Catheter Ablation Tachycardia Ventricular Tachycardia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 16.5 |
| 52 Week Low | 0.2619 |
| Average Volume | 1,169,609 |
| 200-Day Moving Average | 3.14 |
| 50-Day Moving Average | 1.13 |
| 20-Day Moving Average | 1.49 |
| 10-Day Moving Average | 1.44 |
| Average True Range | 0.27 |
| RSI (14) | 57.63 |
| ADX | 37.21 |
| +DI | 31.77 |
| -DI | 13.40 |
| Chandelier Exit (Long, 3 ATRs) | 1.20 |
| Chandelier Exit (Short, 3 ATRs) | 2.01 |
| Upper Bollinger Bands | 1.88 |
| Lower Bollinger Band | 1.10 |
| Percent B (%b) | 0.7 |
| BandWidth | 52.10 |
| MACD Line | 0.09 |
| MACD Signal Line | 0.09 |
| MACD Histogram | -0.006 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.91 | ||||
| Resistance 3 (R3) | 1.91 | 1.83 | 1.86 | ||
| Resistance 2 (R2) | 1.83 | 1.77 | 1.83 | 1.85 | |
| Resistance 1 (R1) | 1.74 | 1.72 | 1.79 | 1.74 | 1.83 |
| Pivot Point | 1.66 | 1.66 | 1.68 | 1.66 | 1.66 |
| Support 1 (S1) | 1.57 | 1.60 | 1.62 | 1.57 | 1.47 |
| Support 2 (S2) | 1.49 | 1.55 | 1.49 | 1.45 | |
| Support 3 (S3) | 1.40 | 1.49 | 1.44 | ||
| Support 4 (S4) | 1.40 |
